Legend Biotech - American Depositary Shares (LEGN) closed at $18.54 on November 12, 2026, down 5.1% from the previous close, on volume of 4,135,927 shares (30-day average 2,148,276).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Diagonal Put Spread | 18-Dec-26 : 21-Jan-2827.5 : 22.5 P | 1,430 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Wed, 11-Nov 8:40 AM ET)
TipRanks (Wed, 11-Nov 8:30 AM ET)
Analysts’ Top Healthcare Picks: Protalix (PLX), Legend Biotech (LEGN)
TipRanks (Wed, 11-Nov 6:50 AM ET)
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN) and Legend Biotech (LEGN)
TipRanks (Wed, 11-Nov 4:01 AM ET)
Legend Biotech GAAP EPS of -$0.13 misses by $0.14, revenue of $359.5M misses by $0.41M
Seeking Alpha News (Tue, 10-Nov 7:03 AM ET)
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
TipRanks (Mon, 9-Nov 9:00 PM ET)
Here are the major earnings before the open Tuesday
Seeking Alpha News (Mon, 9-Nov 6:00 PM ET)
Legend Biotech Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 9-Nov 10:08 AM ET)
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Globe Newswire (Mon, 9-Nov 8:00 AM ET)
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.
As of November 13, 2026, LEGN stock price declined to $18.15 with 1,154,130 million shares trading.
LEGN has a beta of 1.18, meaning it tends to be more sensitive to market movements. LEGN has a correlation of 0.04 to the broad based SPY ETF.
LEGN has a market cap of $3.53 billion. This is considered a Mid Cap stock.
Last quarter Legend Biotech - American Depositary Shares reported $360 million in Revenue and $.14 earnings per share. This fell short of revenue expectation by $-409,248 and exceeded earnings estimates by $.13.
In the last 3 years, LEGN traded as high as $70.13 and as low as $16.24.
The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, PBE, CANC, PINK.
LEGN has underperformed the market in the last year with a price return of -41.8% while the SPY ETF gained +11.0%. LEGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.1% and -18.6%, respectively, while the SPY returned -2.5% and -2.4%, respectively.
LEGN support price is $17.78 and resistance is $19.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.
